<DOC>
	<DOCNO>NCT00698984</DOCNO>
	<brief_summary>The purpose study obtain information effect combination genistein , PUFAs , vitamin K D ( BONISTEIN ( R ) bone blend ) bone health , determine bone mass density/content bone biomarkers 6-months treatment 70 healthy postmenopausal woman . In addition , safety tolerability investigate .</brief_summary>
	<brief_title>Investigation Effect BONISTEIN ( R ) Bone Blend Bone Mineral Density/Content Biomarkers Bone Health</brief_title>
	<detailed_description>Osteoporosis frequent disease skeletal system approximately one third postmenopausal woman currently affect USA Europe . The role nutrition bone health increasingly recognize last couple year . In particular nutrient isoflavones , vitamin D K well polyunsaturated fatty acid ( PUFA ) implicate bone health recently . The DSM Nutritional Products Ltd product BONISTEIN ( R ) synthetic genistein . Its genistin aglycone purity 99 % appearance beige crystal . In addition primary secondary outcome , body composition , genistein plasma level , diet physical activity assess .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamin K</mesh_term>
	<mesh_term>Vitamin K 1</mesh_term>
	<criteria>Female Age 45 ( inclusive ) 55 year ( inclusive ) Race : Caucasian Nonsmokers / Smokers 10 cigarettes/day Postmenopausal hormone status : 13 year since last spontaneous menstrual bleeding folliclestimulating hormone concentration ( FSH ) &gt; 75 IU/ml 17estradiol ( E2 ) &lt; 20 ng/L Years since menopause 13 year Natural menopause total hysterectomy bilateral salpingooophorectomy Subjects E2 result within inclusion criterion range assess individual basis FSH level le 75 IU/ml Assessed agerelated healthy , base prestudy examination include medical history , physical examination , ECG , vital sign clinical laboratory . The examination perform MD study site within 12 month prior plan study start individual subject . Willingness ability give write informed consent willingness ability understand , participate comply study requirement . Ability understand , speak , read write English language Tscore &lt; 2.5 total hip spine ( either ) Suspect lack compliance BMI &gt; 30 &lt; 21 Use HRT within previous 6 month Use drug might interfere bonemetabolism ( bisphosphate , estrogen receptor modulators , calcitonin ) within previous 12 month Systematic practice high intensity exercise Vegetarian nutrition extreme dietary habit Use dietary supplement study , except multi vitamin . No `` wash '' period supplement must stop runin period refrain end study . Participant study donation blood last 30 day start dose phase ( T0 ) . Total genistein blood concentration &gt; 100 ng/ml measure prestudy examination Known hypersensitivity allergy soy , purify isoflavones , peanut , fish , and/or genistein . Hepatitis screen ( serology ) positive perform Drug screen positive perform ( least amphetamine , benzodiazepine , cannabinoides , opiate ) . Subjects weight reduction program medically supervise diet Unexplained weight loss weight gain 5 kg three month prior study History liver pancreas diseases Cardiovascular disease , even AVblock I0 ( PQ time &gt; 220 m ) QTc time &gt; 450 m History breast cancer , endometrial cancer malignancy except basal squamous cell skin cancer History thromboembolism deep venous thrombosis Any fracture within one year except finger , toe facial bone Subjects susceptibility fracture history faller Endometrial thickness &gt; 6 mm Endometrial polyp Untreated hypo hyperthyroidism Insulindependent diabetes mellitus , Crohn 's Disease , Cushing Disease etc . Any condition might interfere absorption investigational product ( e.g . malabsorption syndrome ) Comedication : Anticoagulants , parathyroid hormone , corticosteroid , thiazide diuretic Subjects , previous 24 month , receive total fee payment great 5'000 USD participation biomedical research</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Soy Isoflavones , Bone Mineral Density , Bone Mineral Content , postmenopausal Women , Bone Markers , Bone Health , Phytoestrogens</keyword>
</DOC>